Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | HINT1 | P49773 | 5/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535718 | 0.92 | HINT1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23710671 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL780400 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL2424287 | 0.89 | HINT1 (0.55) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23710670 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23200375 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7111072 | 0.89 | HINT1 (0.55) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23200376 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL800400 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL800874 | 0.89 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
| US-12384813-B2 | Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates | MIRECA MEDICINES GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | MIRECA MEDICINES GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| EP-4399215-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | Mireca Medicines GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-117999269-A | Improved process for producing cyclic guanosine monophosphate analogues | 米雷卡医药有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023031481-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2023-03-09 | — | — | WO | disclosed |
| EP-3353298-A2 | ALLELE SELECTIVE GENE EDITING AND USES THEREOF | Arcturus Therapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3277811-A1 | FULLY STABILIZED ASYMMETRIC SIRNA | University of Massachusetts (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017053431-A2 | ALLELE SELECTIVE GENE EDITING AND USES THEREOF | ARCTURUS THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016161388-A1 | FULLY STABILIZED ASYMMETRIC SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | TAAR1 4143/4885HINT1 1818/4885NT5E 259/4885 |
| US-12384813-B2 | Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates | PRKG1, PRKG2, PRKAG3 | TAAR1 4157/4885HINT1 1775/4885NT5E 228/4885 |
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | GMPS, CGAS, AMPD3 | TAAR1 4182/4885HINT1 285/4885NT5E 111/4885 |
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | TAAR1 2091/4885HINT1 96/4885NT5E 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.